Concept:
The question tests the fundamental differences in the clinical behavior and standard management protocols between Small Cell Lung Carcinoma (SCLC) and Non-Small Cell Lung Carcinoma (NSCLC).
Explanation:
• Small Cell Lung Carcinoma (SCLC) is a highly aggressive, rapidly proliferating neuroendocrine tumor that is almost universally considered a systemic disease at the time of initial diagnosis.
• Because micrometastases are presumed to be present even in early-stage SCLC, surgical resection alone is never considered curative; systemic chemotherapy (often combined with radiotherapy) is the absolute mainstay of treatment.
• Therefore, statement A is completely true.
• Statement B is false because early-stage NSCLC (e.g., Stage I) is primarily managed with definitive surgical resection (lobectomy) and often does not require adjuvant chemotherapy.
• Statement C is false because paraneoplastic syndromes (such as SIADH, ectopic ACTH production, and Lambert-Eaton syndrome) are far more commonly associated with Small Cell Lung Carcinoma than with NSCLC.
• Statement D is false because routine cranio-spinal imaging is a standard staging requirement for SCLC due to its high propensity for brain metastasis, but it is not strictly required for early-stage asymptomatic NSCLC evaluation unless specifically indicated.
Final Answer:
Small cell lung carcinoma is treated as a systemic disease from the outset and cannot be cured by surgical resection alone.